Pure Autonomic Failure Carries 5% Annual Risk of Central Phenoconversion

Pure autonomic failure is a rare neurodegenerative disorder characterized by isolated sympathetic and parasympathetic dysfunction, most commonly manifesting as neurogenic orthostatic hypotension (a significant drop in blood pressure upon standing) [1]. While the pathology is primarily peripheral, involving alpha-synuclein deposition in autonomic ganglia, longitudinal data indicate that a substantial portion of patients will eventually develop central nervous system involvement [2, 3, 4]. Patients often present with non-motor symptoms such as supine hypertension (elevated blood pressure while lying down) and rapid eye movement sleep behavior disorder (a condition where patients physically act out dreams) [5, 6, 7]. Differentiating between those who will remain stable and those destined to develop Parkinson disease, dementia with Lewy bodies, or multiple system atrophy remains a significant diagnostic challenge, as the annual risk of phenoconversion (the transition from a prodromal state to a manifest neurological disease) is difficult to predict [2, 3, 8]. A recent systematic review and meta-analysis provides a framework for estimating these conversion risks and identifying clinical markers that signal impending neurological decline [2].